All In Biotech

Drug Trial Radar · NCT02762578

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2

Last checked: Nov 20, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 543 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

543

Actual

Start

May 3, 2016

Primary completion

May 19, 2017

Study completion Jun 19, 2017

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in subjects with type 2 diabetes.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • insulin degludec/insulin aspartDrug

    Twice daily subcutaneous (sc, under the skin) injection.

  • biphasic insulin aspartDrug

    Twice daily subcutaneous (sc, under the skin) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)Time frame: At 26 weeks

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Tianjin, China

  • Novo Nordisk Investigational Site

    Hefei, Anhui, China

  • Novo Nordisk Investigational Site

    Hefei, Anhui, China

  • Novo Nordisk Investigational Site

    Beijing, Beijing Municipality, China

  • Novo Nordisk Investigational Site

    Beijing, Beijing Municipality, China

  • Novo Nordisk Investigational Site

    Beijing, Beijing Municipality, China

  • Novo Nordisk Investigational Site

    Beijing, Beijing Municipality, China

  • Novo Nordisk Investigational Site

    Beijing, Beijing Municipality, China

  • Novo Nordisk Investigational Site

    Beijing, Beijing Municipality, China

  • Novo Nordisk Investigational Site

    Chongqing, Chongqing Municipality, China

  • Novo Nordisk Investigational Site

    Chongqing, Chongqing Municipality, China

  • Novo Nordisk Investigational Site

    Fuzhou, Fujian, China

  • Novo Nordisk Investigational Site

    Fuzhou, Fujian, China

  • Novo Nordisk Investigational Site

    Guangzhou, Guangdong, China

  • Novo Nordisk Investigational Site

    Guangzhou, Guangdong, China

  • Novo Nordisk Investigational Site

    Guangzhou, Guangdong, China

  • Novo Nordisk Investigational Site

    Guangzhou, Guangdong, China

  • Novo Nordisk Investigational Site

    Nanning, Guangxi, China

  • Novo Nordisk Investigational Site

    Nanning, Guangxi, China

  • Novo Nordisk Investigational Site

    Cangzhou, Hubei, China

  • Novo Nordisk Investigational Site

    Baotou, Inner Mongolia, China

  • Novo Nordisk Investigational Site

    Changzhou, Jiangsu, China

  • Novo Nordisk Investigational Site

    Nanjing, Jiangsu, China

  • Novo Nordisk Investigational Site

    Nanjing, Jiangsu, China

  • Novo Nordisk Investigational Site

    Nanjing, Jiangsu, China

  • Novo Nordisk Investigational Site

    Suzhou, Jiangsu, China

  • Novo Nordisk Investigational Site

    Suzhou, Jiangsu, China

  • Novo Nordisk Investigational Site

    Zhenjiang, Jiangsu, China

  • Novo Nordisk Investigational Site

    Nanchang, Jiangxi, China

  • Novo Nordisk Investigational Site

    Changchun, Jilin, China

  • Novo Nordisk Investigational Site

    Changchun, Jilin, China

  • Novo Nordisk Investigational Site

    Changchun, Jilin, China

  • Novo Nordisk Investigational Site

    Siping, Jilin, China

  • Novo Nordisk Investigational Site

    Jinan, Shandong, China

  • Novo Nordisk Investigational Site

    Shanghai, Shanghai Municipality, China

  • Novo Nordisk Investigational Site

    Shanghai, Shanghai Municipality, China

  • Novo Nordisk Investigational Site

    Shanghai, Shanghai Municipality, China

  • Novo Nordisk Investigational Site

    Shanghai, Shanghai Municipality, China

  • Novo Nordisk Investigational Site

    Shanghai, Shanghai Municipality, China

  • Novo Nordisk Investigational Site

    Chengdu, Sichuan, China

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.